Zornberg G L, Pope H G
Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA 02178.
J Clin Psychopharmacol. 1993 Dec;13(6):397-408.
The objective of the study was to review the clinical literature on the acute, somatic treatment of the depressed phase of bipolar disorder. We reviewed all available published studies of "standard" somatic treatments (lithium, antidepressant and anticonvulsant agents, and electroconvulsive therapy [ECT]) reporting three or more depressed bipolar patients who were not psychotic, rapid cycling, or previously treatment refractory. We also reviewed all studies of "nonstandard" pharmacologic treatments involving even a single case of a depressed bipolar patient. Data sources included the MEDLINE database and relevant references from articles obtained in this search and in major reviews. Five of seven studies comparing ECT with antidepressant agents find ECT more efficacious. Eight of nine controlled comparisons find lithium superior to placebo in depressed bipolar patients. Three controlled comparisons of lithium to tricyclic antidepressants suggest that lithium is equivalent to tricyclic drugs in such patients. Three double-blind, controlled studies indicate that carbamazepine is more effective than placebo. Limited data on other antidepressant classes suggest that monoamine oxidase inhibitors, bupropion, and serotonergic agents may offer some advantages over tricyclic antidepressants in this population. Some "nonstandard" treatments also show some potential in bipolar patients. The possibility of switching into a manic episode is an important consideration with many of the agents studied, although little remains known about spontaneous versus treatment-associated mood shifts. In contrast to the extensive literature on the acute treatment of the manic phase of bipolar disorder and on the prophylaxis of manic and depressive episodes, there are few studies of treatment of the depressed phase of bipolar disorder, and their results generally are limited or inconclusive. Lithium generated a revolution in psychiatric treatment, but the treatment of the depressed phase of bipolar disorder remains a relatively neglected corner of the field. Several study designs may help to augment knowledge in the treatment of bipolar depression.
该研究的目的是回顾关于双相情感障碍抑郁期急性躯体治疗的临床文献。我们检索了所有已发表的关于“标准”躯体治疗(锂盐、抗抑郁药、抗惊厥药以及电休克治疗[ECT])的研究,这些研究报告了三名或更多非精神病性、非快速循环型或既往治疗无效的双相抑郁患者。我们还检索了所有涉及哪怕仅一例双相抑郁患者的“非标准”药物治疗研究。数据来源包括MEDLINE数据库以及本次检索和主要综述中所获文章的相关参考文献。七项比较ECT与抗抑郁药的研究中有五项发现ECT更有效。九项对照比较中有八项发现锂盐在双相抑郁患者中优于安慰剂。三项锂盐与三环类抗抑郁药的对照比较表明,锂盐在这类患者中与三环类药物等效。三项双盲对照研究表明卡马西平比安慰剂更有效。关于其他抗抑郁药类别的有限数据表明,单胺氧化酶抑制剂、安非他酮和5-羟色胺能药物在这类人群中可能比三环类抗抑郁药具有一些优势。一些“非标准”治疗在双相情感障碍患者中也显示出一定潜力。对于许多所研究的药物,转变为躁狂发作的可能性是一个重要的考虑因素,尽管对于自发的与治疗相关的情绪转变仍知之甚少。与关于双相情感障碍躁狂期急性治疗以及躁狂和抑郁发作预防的大量文献相比,关于双相情感障碍抑郁期治疗的研究较少,其结果通常有限或无定论。锂盐引发了精神科治疗的一场革命,但双相情感障碍抑郁期的治疗仍然是该领域一个相对被忽视的角落。几种研究设计可能有助于增加对双相抑郁治疗的认识。